Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data

Risk of Cardiovascular Events and All-Cause Mortality in Patients Treated With Thiazolidinediones in a Managed-Care Population

(2010) Debra A. Wertz et al.  

The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database

(2010) Najat Ziyadeh et al.   CLINICAL THERAPEUTICS

Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone

(2010) David J. Graham et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD)

(2010) Dori Bilik et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Validation and validity of diagnoses in the General Practice Research Database: a systematic review

(2009) Emily Herrett et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients

(2009) Alain Vanasse et al.   Diabetes & Vascular Disease Research

Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records

(2009) J. S. Brownstein et al.   DIABETES CARE

Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus

(2009) Fei-Yuan Hsiao et al.   DRUG SAFETY

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

(2009) Philip D Home et al.   LANCET

Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis

(2009) Zeina A. Habib et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction

(2009) David D Dore et al.   PHARMACOTHERAPY

Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin

(2009) Colin R. Dormuth et al.   PLoS One

A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example

(2009) Tjeerd-Pieter van Staa et al.   PLOS MEDICINE

Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy

(2008) Wolfgang C. Winkelmayer et al.   ARCHIVES OF INTERNAL MEDICINE

Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007

(2008) Alexander M. Walker et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients

(2008) Carol E. Koro et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Association between serious ischemic cardiac outcomes and medications used to treat diabetes

(2008) David J. Margolis et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications

(2008) Karen M. Stockl et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY